Adlai Nortye (NASDAQ:ANL) CFO Xiaofeng Ye Sells 6,000 Shares

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00. Following the completion of the sale, the chief financial officer owned 153,424 shares of the company’s stock, valued at approximately $2,144,867.52. This trade represents a 3.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Wednesday, August 26th, Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75.

Adlai Nortye Stock Up 9.6%

Shares of ANL stock opened at $15.06 on Thursday. The firm has a fifty day moving average of $12.00 and a two-hundred day moving average of $11.16. Adlai Nortye Ltd. Sponsored ADR has a 1-year low of $0.88 and a 1-year high of $17.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65.

Institutional Investors Weigh In On Adlai Nortye

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SmartHarvest Portfolios LLC grew its position in Adlai Nortye by 8.5% in the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after buying an additional 1,279 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Adlai Nortye in the 1st quarter worth approximately $457,000. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the first quarter valued at approximately $1,140,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye in the first quarter valued at approximately $816,000. Finally, Boone Capital Management LLC acquired a new position in shares of Adlai Nortye during the second quarter valued at approximately $2,971,000. 35.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ANL. Oppenheimer initiated coverage on Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price objective for the company. Wall Street Zen upgraded Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. JonesTrading began coverage on Adlai Nortye in a report on Thursday, May 14th. They issued a “buy” rating and a $22.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They set an “overweight” rating for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.25.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.